Shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) traded up 11.9% during trading on Wednesday . The stock traded as high as $0.46 and last traded at $0.47. 48,977 shares changed hands during trading, a decline of 95% from the average session volume of 1,079,833 shares. The stock had previously closed at $0.42.
Several analysts recently commented on the company. HC Wainwright set a $6.00 price objective on Aralez Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 15th. Bloom Burton downgraded Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research note on Wednesday, March 14th. ValuEngine raised Aralez Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Aralez Pharmaceuticals in a research note on Tuesday, March 20th.
The firm has a market capitalization of $26.88 million, a PE ratio of -0.38 and a beta of 1.39. The company has a quick ratio of 0.75, a current ratio of 0.80 and a debt-to-equity ratio of -41.79.
In other news, insider Andrew I. Koven sold 156,573 shares of the firm’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $0.37, for a total value of $57,932.01. Following the completion of the transaction, the insider now owns 1,183,419 shares in the company, valued at approximately $437,865.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 176,262 shares of company stock valued at $74,926 in the last 90 days. 10.30% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Salzhauer Michael grew its holdings in shares of Aralez Pharmaceuticals by 107.1% in the 1st quarter. Salzhauer Michael now owns 220,153 shares of the company’s stock valued at $330,000 after acquiring an additional 113,860 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Aralez Pharmaceuticals by 159.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 261,606 shares of the company’s stock worth $371,000 after purchasing an additional 160,621 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Aralez Pharmaceuticals by 48.3% during the first quarter. Wells Fargo & Company MN now owns 1,018,731 shares of the company’s stock worth $1,529,000 after purchasing an additional 331,800 shares during the period. Institutional investors own 15.83% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.